Bristol-Myers Squibb Company
STABLE FORMULATIONS OF FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN

Abstract:

The present invention relates generally to stable liquid formulations comprising polypeptides with .sup.10Fn3 domains which bind to myostatin and unit dosage forms thereof for administration various routes, including subcutaneous (SC), for treating muscle-wasting and metabolic disorders.